Overview

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To improve the clinical outcomes of patients with non-small cell lung cancer treated with radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Ontario Clinical Oncology Group (OCOG)
Collaborator:
Roche Pharma AG
Treatments:
Erlotinib Hydrochloride